{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-090181","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-08-14T20:35:17+00:00","discovered_at":"2026-08-14T20:40:32.717277+00:00","generated_at":"2026-08-14T20:44:47.678771+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Citius Pharma Q3 FY26: LYMPHIR revenue $1.5M, net loss $8.9M, cash $17M","bullets":["Q3 FY26 revenue $1.5M from LYMPHIR (vs $0 prior year); nine-month revenue $7.1M.","Net loss $8.9M ($0.34/share) for Q3; $38.3M ($1.64/share) for nine months.","Cash and equivalents $17.0M at June 30, 2026; raised $4.5M offering, $9.7M warrants, $10M loan.","LYMPHIR now at 44 institutions; institutional vial orders up 31%, new institutions up 80%; July orders 383 vials.","G&A includes $19.7M non-recurring contract cancellation charge in March 2026; commercial team expanded to 29."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-090181","json":"https://secwatch.observer/filing/0001213900-26-090181.json","markdown":"https://secwatch.observer/filing/0001213900-26-090181.md","text":"https://secwatch.observer/filing/0001213900-26-090181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026090181/0001213900-26-090181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026090181/ea0302227-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:44:47.678771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}